WO2012011129A3 - Nouveau polymorphe de sel de calcium d'acide bis[(e)-7-[4-(4-fluorophényl)-6-iso-propyl-2-[méthyl (méthylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-énoïque] - Google Patents

Nouveau polymorphe de sel de calcium d'acide bis[(e)-7-[4-(4-fluorophényl)-6-iso-propyl-2-[méthyl (méthylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-énoïque] Download PDF

Info

Publication number
WO2012011129A3
WO2012011129A3 PCT/IN2011/000485 IN2011000485W WO2012011129A3 WO 2012011129 A3 WO2012011129 A3 WO 2012011129A3 IN 2011000485 W IN2011000485 W IN 2011000485W WO 2012011129 A3 WO2012011129 A3 WO 2012011129A3
Authority
WO
WIPO (PCT)
Prior art keywords
dihydroxyhept
methylsulfonyl
pyrimidin
fluorophenyl
iso
Prior art date
Application number
PCT/IN2011/000485
Other languages
English (en)
Other versions
WO2012011129A2 (fr
Inventor
Manne Satyanarayana Reddy
Srinivasan Thirumalai Rajan
Maramreddy Sahadeva Reddy
Ningam Srinivasa Reddy
Original Assignee
Msn Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Msn Laboratories Limited filed Critical Msn Laboratories Limited
Publication of WO2012011129A2 publication Critical patent/WO2012011129A2/fr
Publication of WO2012011129A3 publication Critical patent/WO2012011129A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un nouveau polymorphe de sel de calcium d'acide bis[(e)-7-[4-(4-fluorophényl)-6-iso-propyl-2-[méthyl(méthylsulfonyl)amino] pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-énoïque].
PCT/IN2011/000485 2010-07-22 2011-07-21 Nouveau polymorphe de sel de calcium d'acide bis[(e)-7-[4-(4-fluorophényl)-6-iso-propyl-2-[méthyl (méthylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-énoïque] WO2012011129A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2088/CHE/2010 2010-07-22
IN2088CH2010 2010-07-22

Publications (2)

Publication Number Publication Date
WO2012011129A2 WO2012011129A2 (fr) 2012-01-26
WO2012011129A3 true WO2012011129A3 (fr) 2012-03-15

Family

ID=45497235

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2011/000485 WO2012011129A2 (fr) 2010-07-22 2011-07-21 Nouveau polymorphe de sel de calcium d'acide bis[(e)-7-[4-(4-fluorophényl)-6-iso-propyl-2-[méthyl (méthylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-énoïque]

Country Status (1)

Country Link
WO (1) WO2012011129A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014050874A1 (fr) * 2012-09-27 2014-04-03 東和薬品株式会社 Nouvelle forme cristalline de rosuvastatine de calcium et son procédé de fabrication
WO2017183040A1 (fr) * 2016-04-18 2017-10-26 Morepen Laboratories Limited Nouvelle forme polymorphe de rosuvastatine calcique cristalline et nouveaux procédés pour la rosuvastatine calcique cristalline et amorphe
CN105837516B (zh) * 2016-05-16 2018-07-10 山东新时代药业有限公司 一种瑞舒伐他汀钙晶型及其制备方法

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000049014A1 (fr) * 1999-02-17 2000-08-24 Astrazeneca Ab Procede de production de tert-butyl (e)-(6-[2- [4-(4-fluorophenyl) -6-isopropyl-2-[ methyl (methylsulfonyl) amino] pyrimidin-5-yl] vinyl](4r, 6s)-2,2-dimethyl [1,3]dioxan-4-yl) acetate
WO2003097614A2 (fr) * 2002-05-21 2003-11-27 Ranbaxy Laboratories Limited Procede de preparation de rosuvastatine
WO2004052867A1 (fr) * 2002-12-10 2004-06-24 Ranbaxy Laboratories Limited Procede de preparation de rosuvastatine
WO2004108691A1 (fr) * 2003-06-05 2004-12-16 Astrazeneca Uk Limited Production amelioree du sel de calcium de rosuvastatine
WO2005051921A1 (fr) * 2003-11-24 2005-06-09 Teva Pharmaceutical Industries Ltd. Sels d'ammonium cristallins de la rosuvastatine
CN1733737A (zh) * 2005-08-22 2006-02-15 鲁南制药集团股份有限公司 瑞舒伐他汀及其盐的制备方法
CN1763015A (zh) * 2004-10-22 2006-04-26 四川抗菌素工业研究所有限公司 一种罗舒伐他汀及其药用盐的制备方法及中间体
WO2006100689A1 (fr) * 2005-03-22 2006-09-28 Unichem Laboratories Limited Procede de preparation de la rosuvastatine
WO2007017117A1 (fr) * 2005-07-28 2007-02-15 Lek Pharmaceuticals D.D. Processus destine a la synthese de calcium rosuvastatine
WO2008044243A2 (fr) * 2006-10-09 2008-04-17 Manne Satyanarayana Reddy Nouveau procédé de préparation de statines et leurs sels pharmaceutiquement acceptables
US20080091014A1 (en) * 2005-01-19 2008-04-17 Anhui Quingyun Pharmaceutical And Chemical Co., Ltd. Synthetic Method and Intermediates of Rosuvastatin Calcium and Preparation Methods of Intermediates
WO2008065410A1 (fr) * 2006-12-01 2008-06-05 Astrazeneca Uk Limited Procédé de fabrication de rosuvastatine
CN101376647A (zh) * 2007-08-31 2009-03-04 中山奕安泰医药科技有限公司 一种用于合成瑞舒伐他汀中间体及瑞舒伐他汀的合成方法
CA2725052A1 (fr) * 2008-05-27 2009-12-03 Changzhou Pharmaceutical Factory Co., Ltd. Procede de preparation de la rosuvastatine calcique et de ses intermediaires

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000049014A1 (fr) * 1999-02-17 2000-08-24 Astrazeneca Ab Procede de production de tert-butyl (e)-(6-[2- [4-(4-fluorophenyl) -6-isopropyl-2-[ methyl (methylsulfonyl) amino] pyrimidin-5-yl] vinyl](4r, 6s)-2,2-dimethyl [1,3]dioxan-4-yl) acetate
WO2003097614A2 (fr) * 2002-05-21 2003-11-27 Ranbaxy Laboratories Limited Procede de preparation de rosuvastatine
WO2004052867A1 (fr) * 2002-12-10 2004-06-24 Ranbaxy Laboratories Limited Procede de preparation de rosuvastatine
WO2004108691A1 (fr) * 2003-06-05 2004-12-16 Astrazeneca Uk Limited Production amelioree du sel de calcium de rosuvastatine
WO2005051921A1 (fr) * 2003-11-24 2005-06-09 Teva Pharmaceutical Industries Ltd. Sels d'ammonium cristallins de la rosuvastatine
CN1763015A (zh) * 2004-10-22 2006-04-26 四川抗菌素工业研究所有限公司 一种罗舒伐他汀及其药用盐的制备方法及中间体
US20080091014A1 (en) * 2005-01-19 2008-04-17 Anhui Quingyun Pharmaceutical And Chemical Co., Ltd. Synthetic Method and Intermediates of Rosuvastatin Calcium and Preparation Methods of Intermediates
WO2006100689A1 (fr) * 2005-03-22 2006-09-28 Unichem Laboratories Limited Procede de preparation de la rosuvastatine
WO2007017117A1 (fr) * 2005-07-28 2007-02-15 Lek Pharmaceuticals D.D. Processus destine a la synthese de calcium rosuvastatine
CN1733737A (zh) * 2005-08-22 2006-02-15 鲁南制药集团股份有限公司 瑞舒伐他汀及其盐的制备方法
WO2008044243A2 (fr) * 2006-10-09 2008-04-17 Manne Satyanarayana Reddy Nouveau procédé de préparation de statines et leurs sels pharmaceutiquement acceptables
WO2008065410A1 (fr) * 2006-12-01 2008-06-05 Astrazeneca Uk Limited Procédé de fabrication de rosuvastatine
CN101376647A (zh) * 2007-08-31 2009-03-04 中山奕安泰医药科技有限公司 一种用于合成瑞舒伐他汀中间体及瑞舒伐他汀的合成方法
CA2725052A1 (fr) * 2008-05-27 2009-12-03 Changzhou Pharmaceutical Factory Co., Ltd. Procede de preparation de la rosuvastatine calcique et de ses intermediaires

Also Published As

Publication number Publication date
WO2012011129A2 (fr) 2012-01-26

Similar Documents

Publication Publication Date Title
HRP20190012T1 (hr) Novi fuzionirani pirimidin derivati za inhibiciju aktivnosti tirozin kinaze
TWI341310B (en) Improved production of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid calcium salt
IS2689B (is) Kristallað form bis [(E)-7-[4-(4-flúorfenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl) amínó]pýrimídin-5-ýl](3R, 5S)-3,5-díhýdroxýhept-6-ensýru] kalsíumsalts
WO2009157014A3 (fr) Procédé d'élaboration d'inhibiteurs de hmg-coa réductase et d'intermédiaires correspondants
IS8478A (is) Aðferð til að framleiða kalsíumsalt rósúvatatín (E)-7-[4-(4-flúorfenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl)amínó]pýrimídín-5-ýl] (3R,5S)-3,5-díhýdroxýhept-6-enósýru og kristölluð milliefni þess
IL227904A (en) Bite-3, 6- (4-Aminoalkyl) -5,2-Nitrogen-Protected Dictopyrazine
CU23886B1 (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteínas quinasas b
WO2012025944A3 (fr) Sitagliptine, sels et polymorphes de celle-ci
MY180039A (en) N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator
WO2011099764A3 (fr) Nouveau dérivé de la pyrimidine pour l'inhibition de la croissance des cellules cancéreuses
ZA200807158B (en) Malate salts, and polymorphs of (3S,5S)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1, 4-dihydro-8-methoxy-4-oxo-3-quinolinecaroxylic acid
EA201390771A1 (ru) Способ получения фармацевтических промежуточных соединений высокой чистоты
WO2012011129A3 (fr) Nouveau polymorphe de sel de calcium d'acide bis[(e)-7-[4-(4-fluorophényl)-6-iso-propyl-2-[méthyl (méthylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-énoïque]
ATE553098T1 (de) Verfahren zur herstellung von rosuvastatin- calcium
PL1704144T3 (pl) Sposób wytwarzania soli wapniowej kwasu (E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo](3R,5S)-3,5-dihydroksy-6-heptenowego
WO2012063115A3 (fr) Procédé de préparation de rosuvastatine calcique via un nouvel intermédiaire amine
WO2012073054A3 (fr) Procédé de préparation de sels de rosuvastatine
PL386051A1 (pl) Stabilna doustna kompozycja farmaceutyczna zawierająca farmaceutycznie dopuszczalną sól kwsu [(E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo] (3R,5S)-3,5-dihydroksyhept-6-enowego
ES2409805R1 (es) Nueva sal de un derivado de pirimidina
WO2009091346A3 (fr) Formulation pharmaceutique stable et procédés de préparation
EA201200765A1 (ru) Способ получения полиморфной модификации холиновой соли производного пиримидин-5-илуксусной кислоты

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11809383

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11809383

Country of ref document: EP

Kind code of ref document: A2